Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment

JAMA - Journal of the American Medical Association

Volumn 318, Issue 2, 2017, Pages 132-145

  Mohamed, Somaia ^a,b   Johnson, Gary R ^a   Chen, Peijun ^c   Hicks, Paul B ^d,e   Davis, Lori L ^f,g   Yoon, Jean ^h   Gleason, Theresa C ⁱ   Vertrees, Julia E ^j   Weingart, Kimberly ^k,l   Tal, Ilanit ^k   Scrymgeour, Alexandra ^j   Lawrence, David D ^a   Planeta, Beata ^a   Thase, Michael E ^f   Huang, Grant D ⁱ   Rao, Sanjai D ^m   Pilkinton, Patricia D ^m   Wilcox, James A ^m   Ali Iranmanesh, A I ^m   Sapra, Mamta ^m   Jurjus, George ^m   Michalets, James P ^m   Aslam, Muhammed ^m   Beresford, Thomas ^m   Anderson, Keith D ^m   Fernando, Ronald ^m   Ramaswamy, Sriram ^m   Kasckow, John ^m   Westermeyer, Joseph ^m   Yoon, Gihyun ^m   Cyril D'Souza D ^m   Larson, Gunnar ^m   Anderson, William G ^m   Klatt, Mary ^m   Fareed, Ayman ^m   Thompson, Shabnam I ^m   Carrera, Carlos J ^m   Williams, Solomon S ^m   Juergens, Timothy M ^m   Albers, Lawrence J ^m   Nasdahl, Clifford S ^m   Villarreal, Gerardo ^m   Winston, Julia L ^m   Nogues, Cristobal A ^m   Ryan Connolly, K ^m   Tapp, Andre ^m   Jones, Kari A ^m   Khatkhate, Gauri ^m   Marri, Sheetal ^m   Suppes, Trisha ^m   LaMotte, Joseph ^m   Hurley, Robin ^m   Mayeda, Aimee R ^m   Niculescu III, Alexander B ^m   Fischer, Bernard A ^m   Loreck, David J ^m   Rosenlicht, Nicholas ^m   Lieske, Steven ^m   Finkel, Mitchell S ^m   Little, John T ^m   more..

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^e Central Texas Veterans Health System   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^h Health Economics Resource Center   (United States)

ⁱ DEPARTMENT OF VETERANS AFFAIRS   (United States)

^j University of New Mexico   (United States)

^k VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m University of California ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; GLUCOSE; MIRTAZAPINE; NEUROLEPTIC AGENT; PAROXETINE; SERTRALINE; VENLAFAXINE;

ABDOMINAL PAIN; ABNORMAL DREAMING; ADULT; AGITATION; AKATHISIA; ANGER; ANXIETY; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; DYSTONIA; ELEVATED BLOOD PRESSURE; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOMANIA; INCREASED APPETITE; INSOMNIA; IRRITABILITY; LABORATORY TEST; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENSTRUAL IRREGULARITY; MENTAL DISEASE; MIDDLE AGED; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; NERVOUSNESS; PARALLEL DESIGN; PARKINSONISM; PRIORITY JOURNAL; PRURITUS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; REMISSION; RESTLESSNESS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; TARDIVE DYSKINESIA; TINNITUS; TREATMENT OUTCOME; TREMOR; UNITED STATES; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DEPRESSIVE DISORDER, MAJOR; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SUBSTITUTION; VETERAN;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; BUPROPION; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; DRUG SUBSTITUTION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; UNITED STATES; VETERANS;

EID: 85024390260     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.8036     Document Type: Article

References (30)

1. Murray CJ, Atkinson C, Bhalla K, et al; US Burden of Disease Collaborators. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA. 2013;310(6):591-608.
2. Center for Behavioral Health Statistics and Quality. Key substance use and mental health indicators in the United States: results from the 2015 National Survey on Drug Use and Health. https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2015/NSDUH-FFR1-2015/NSDUH-FFR1-2015.pdf. Accessed June 19, 2017.
3. Cleare A, Pariante CM, Young AH, et al; Members of the Consensus Meeting. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459-525.
4. Kolovos S, van TulderMW, Cuijpers P, et al. The effect of treatment as usual on major depressive disorder: ameta-analysis. J Affect Disord. 2017;210:72-81.
5. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed. Arlington, VA: American Psychiatric Association; 2010.
6. Management of MDDWorking Group. Clinical practice guideline: management of major depressive disorder (MDD). https://www.healthquality.va.gov/mdd/mdd-full09-c.pdf. Accessed June 19, 2017.
7. Kennedy SH, Lam RW, McIntyre RS, et al; CANMAT DepressionWork Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3: pharmacological treatments. Can J Psychiatry. 2016;61(9):540-560.
8. Goldberg JF, Freeman MP, Balon R, et al. The American Society of Clinical Psychopharmacology survey of psychopharmacologists' practice patterns for the treatment of mood disorders. Depress Anxiety. 2015;32(8):605-613.
9. Rush AJ, Trivedi MH, Wisniewski SR, et al; STARD Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231-1242.
10. Trivedi MH, Fava M, Wisniewski SR, et al; STARD Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-1252.
11. Rush AJ,Warden D, Wisniewski SR, et al. STARD: revising conventional wisdom. CNS Drugs. 2009;23(8):627-647.
12. Mohamed S, Leslie DL, Rosenheck RA. Use of antipsychotics in the treatment of major depressive disorder in the US Department of Veterans Affairs. J Clin Psychiatry. 2009;70(6):906-912.
13. Arbaizar B, Dierssen-Sotos T, Gómez-Acebo I, Llorca J. Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials. Gen Hosp Psychiatry. 2009;31(5):478-483.
14. Han C,Wang S-M, Kwak K-P, et al. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: a 6-week, randomized, rater-blinded, prospective study. J Psychiatr Res. 2015;66-67:84-94.
15. Mohamed S, Johnson GR, Vertrees JE, et al. The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: rationale and design considerations. Psychiatry Res. 2015;229(3):760-770.
16. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613.
17. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583.
18. Trivedi MH. Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission. J Clin Psychiatry. 2009;70 (suppl 6):26-31.
19. Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA; STARD Investigators. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract. 2006;12(2):71-79.
20. Israel JA. Remission in depression: definition and initial treatment approaches. J Psychopharmacol. 2006;20(3)(suppl):5-10.
21. GuyW. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: Dept of Health, Education, andWelfare; 1976.
22. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986;22(2):343-381.
23. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
24. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988; 75(4):800-802.
25. Zisook S, Tal I,Weingart K, et al. Characteristics of US veteran patients with major depressive disorder who require "next-step" treatments: a VAST-D report. J Affect Disord. 2016;206:232-240.
26. FavaM, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STARD report. Am J Psychiatry. 2008;165(3):342-351.
27. Sansone RA, Sansone LA. Antidepressant adherence: are patients taking their medications? Innov Clin Neurosci. 2012;9(5-6):41-46.
28. Adams JR, Drake RE. Shared decision-making and evidence-based practice. Community Ment Health J. 2006;42(1):87-105.
29. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004; 65(2):267-272.
30. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report. Am J Psychiatry. 2006;163 (11):1905-1917.